证券代码：600587 证券简称：新华医疗 编号：临 2025-043 山东新华医疗器械股份有限公司 第十一届董事会第二十一次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假 记载、误导性陈述或者重大遗漏负连带责任。 一、董事会会议召开情况 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）第十 一届董事会第二十一次会议于 2025 年 9 月 30 日以书面或通讯方式通知全体董事， 据此通知，会议于 2025 年 10 月 10 日在公司三楼会议室召开。会议以现场与通 讯相结合的方式召开，会议应到董事 11 名，实到 11 名，公司监事和高级管理人 员列席了会议，会议由董事长王玉全先生主持，会议程序符合《公司法》和《公 司章程》的规定。 二、董事会会议审议情况 （一）审议通过《关于取消监事会、修订<公司章程>及相关议事规则的议案》 为进一步提升公司规范运作水平，根据《中华人民共和国公司法》《关于新< 公司法>配套制度规则实施相关过渡期安排》《上市公司章程指引（2025 年修订）》 《上海证券交易所股票上市规则（2025 年 4 月修订）》等法律法规、部门规章及 规 ...

证券代码：600587 证券简称：新华医疗 编号：临 2025-047 山东新华医疗器械股份有限公司 关于 2025 年中期利润分配预案的公告 每股分配比例：山东新华医疗器械股份有限公司（以下简称"公司"或 "新华医疗"）拟向全体股东每 10 股派发现金红利 2.50 元（含税），不进行资本 公积金转增股本，不送红股。 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日 期将在权益分派实施公告中明确。在实施权益分派的股权登记日前公司总股本发 生变动的，公司拟维持现金派发每股分配比例不变，相应调整现金派发总金额， 并将在相关公告中披露。 公司 2025 年中期利润分配方案已经公司第十一届董事会第二十一次会 议、第十一届监事会第二十一次会议审议通过。根据 2024 年年度股东大会审议 通过的 2025 年中期利润分配授权安排，本次利润分配方案无需提交公司股东大 会审议。 一、公司 2025 年中期利润分配预案 新华医疗 2025 年半年度归属于上市公司股东的净利润为 385,717,607.04 元，截至 2025 年 6 月 30 日，公司期末可供分配利润为人民币 4,158,106,651.17 ...

Core Viewpoint - The "Yimeng Spirit" theme宣讲活动 aims to promote the values of unity, sacrifice, and dedication among the people of Shandong, emphasizing the importance of red culture and its historical significance in contemporary society [2][4]. Group 1: Event Overview - The "Yimeng Spirit" theme宣讲活动 was organized by various provincial departments, including the Provincial Party School and the Provincial Culture and Tourism Department, with over 3,200 events held across the province, reaching an audience of 440,000 people [2][4]. - The first event took place on August 21, featuring over 420 representatives who experienced the Yimeng Spirit through various forms of performance, including songs and dramas [3][5]. Group 2: Content and Methodology - The宣讲活动 incorporates a mix of theoretical discussions, performances, and storytelling to engage the audience, moving away from abstract concepts to more relatable narratives [7][8]. - The content focuses on the historical roots of the Yimeng Spirit, its connection to the Party's leadership, and its relevance in modern society, addressing key questions about why and how to promote this spirit [4][6]. Group 3: Expert Involvement - Experts from various academic institutions and research organizations participated in the宣讲活动, enhancing its credibility and depth through well-researched presentations [5][9]. - The activities are designed to resonate with local history and culture, integrating stories from significant historical events to illustrate the enduring values of the Yimeng Spirit [5][9]. Group 4: Future Plans - The initiative will continue to evolve, with plans for regular宣讲活动 that align with local needs and significant historical dates, ensuring the ongoing transmission of the Yimeng Spirit [10].

Investment Rating - The industry rating is "Positive" (maintained) [7] Core Views - The report highlights that the domestic innovative drug sector is entering a phase of "engineer dividend" realization, with improved profitability and valuation breakthroughs expected [1] - The CXO sector is showing signs of recovery, with a positive outlook on CDMO commercialization orders and clinical CRO investment opportunities [2] - The upstream research sector is anticipated to benefit from a downward interest rate cycle and a recovery in global new drug development demand, with recommended stocks including Haoyuan Pharmaceutical and Bid Pharma [3] - The medical device sector is expected to experience a recovery cycle, particularly for high-value consumables and medical equipment companies, with recommendations for companies like Aikang Medical and Mindray Medical [4] - The traditional Chinese medicine sector is projected to see an earnings inflection point, with a favorable outlook for the second half of 2025 [5] - The report favors leading pharmacy chains with superior management capabilities, recommending companies such as Dazhonglin and Yifeng Pharmacy [6] - The pharmaceutical distribution sector is expected to improve, with a focus on low-positioned value and innovative business opportunities [7] Summary by Sections Innovative Drugs - Positive outlook on profitability improvement and valuation breakthroughs due to recognition by multinational corporations [1] CXO - Recovery in the sector with ongoing commercialization of small and large molecule CDMO orders [2] Upstream Research - Anticipated performance elasticity and new business expansion opportunities [3] Medical Devices - Significant growth potential in high-value consumables and medical equipment sectors [4] Traditional Chinese Medicine - Expected earnings growth and increased market interest due to improved fundamentals [5] Pharmacies - Favorable view on pharmacy chains with strong management and adaptability [6] Pharmaceutical Distribution - Positive trends in the sector with potential for operational improvements and value re-evaluation [7]

Overview - The demand for blood dialysis in China is rapidly increasing due to a large patient population and the inclusion of end-stage renal disease treatment in major illness insurance, which has improved reimbursement rates, significantly boosting market demand for blood dialysis [1][13] - The blood dialysis tubing market is projected to reach 1.364 billion yuan in 2024, with a year-on-year growth of 7.01% [1][13] - There remains a significant gap in dialysis treatment rates between China and Western countries, indicating potential for future growth as medical standards improve and insurance coverage expands [1][13] Industry Barriers - The blood dialysis tubing is classified as a Class III medical device in China, which entails strict licensing and supervision, creating high entry barriers for new companies [6] Market Policies - The Chinese government has implemented various policies to support the development of the medical device industry, including blood dialysis tubing, ensuring product quality and patient safety [9] Industry Chain - The upstream of the blood dialysis tubing industry includes suppliers of medical-grade materials and functional additives, while the midstream consists of manufacturing companies, and the downstream includes hospitals and dialysis centers [11] Current Development - The number of patients undergoing blood dialysis in China is expected to reach 1.0273 million in 2024, with a year-on-year increase of 12.04%, indicating a growing market for blood dialysis tubing [12] Competitive Landscape - The market was initially dominated by foreign companies like Fresenius Medical and B. Braun, but domestic companies such as Weigao Blood Purification and Tianyi Medical have gained significant market share due to improved technology and product quality [14] - Weigao Blood Purification is recognized as a leading domestic player, with a total revenue of 3.604 billion yuan in 2024, of which blood dialysis tubing contributed 0.495 billion yuan [14][15] Future Trends - Domestic manufacturers are expected to continue improving in technology and product quality, leading to a more pronounced trend of domestic substitution in the blood dialysis tubing market [16]

Overview - The demand for hemodialysis in China is rapidly increasing due to a large patient population and the inclusion of end-stage renal disease treatment in major illness insurance, which has improved reimbursement rates, significantly boosting market demand for hemodialysis devices [1][8] - The market size of the hemodialyzer industry in China is projected to reach 5.322 billion yuan in 2024, with a year-on-year growth of 0.48% [1][8] Market Policies - The Chinese government has implemented various policies to support the development of the medical device industry, including hemodialyzers, ensuring market order, product quality, and patient safety [4][5] Industry Chain - The hemodialyzer industry chain consists of upstream suppliers of hollow fibers and dialysis membrane materials, midstream manufacturers producing various types of hemodialyzers, and downstream medical institutions such as public hospitals and independent dialysis centers [6][7] Current Development - The number of hemodialysis patients in China is expected to reach 1.0273 million in 2024, representing a year-on-year increase of 12.04%, with a notable rise in the average age of patients [8] - The male patient proportion is 61.3%, with new male patients accounting for 63.9% [8] Competitive Landscape - The hemodialyzer market in China was initially dominated by foreign companies, but domestic companies like Weigao Blood Purification and Sanxin Medical have been increasing their market share due to improved R&D capabilities and local cost advantages [9][11] - The shift from price competition to quality and innovation is evident, driven by regulatory changes and procurement policies [9] Key Companies - Weigao Blood Purification, a leading player in the blood purification industry, reported a total revenue of 3.604 billion yuan in 2024, with hemodialyzer revenue accounting for 51% of total revenue [11] - Sanxin Medical, established in 1997, achieved a total revenue of 1.5 billion yuan in 2024, with blood purification-related business contributing 81.13% of total revenue [11][12] Future Trends - The implementation of volume-based procurement policies is expected to lower product prices, leading to increased industry concentration as less competitive companies may exit the market [13] - Hemodialyzer companies are likely to offer integrated solutions combining equipment, consumables, and services to enhance customer satisfaction and market competitiveness [13]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600587 证券简称：新华医疗 公告编号：临2025-041 山东新华医疗器械股份有限公司 关于控股股东增持计划进展暨权益变动触及1%刻度的提示性公告 控股股东山东颐养健康产业发展集团有限公司保证向本公司提供的信息真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 1.身份类别 ■ 2.信息披露义务人信息 上述信息披露义务人无一致行动人。 二、权益变动触及1%刻度的基本情况 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： ● 本次权益变动为山东新华医疗器械股份有限公司（以下简称"公司"）控股股东山东颐养健康产业发展 集团有限公司（以下简称"山东健康集团"）按照增持计划增持公司股份，不触及要约收购，不会导致公 司控股股东及实际控制人发生变化。 ● 本次权益变动后，山东健康集团合计持有公司股份175,936,527股，占公司总股本的29.00%。 ■ 一、信息披露义务人及其一致行动人的基本信息 ■ 三、其他说明 1.本次权益变动为山东健康集团履行此前披露的增持股份计划，不触及要约收购。 2.本次权益变动不会导致 ...

Investment Rating - The report assigns an investment rating of "Positive" for the traditional Chinese medicine (TCM) industry, indicating an optimistic outlook for the sector over the next 12 months [6]. Core Insights - The TCM industry is experiencing a resurgence due to supportive government policies aimed at promoting its development and modernization. The report highlights the importance of innovation in TCM as a key driver for high-quality growth [24][61]. - The industry is characterized by a comprehensive supply chain, from raw material production to manufacturing and distribution, with significant opportunities for growth in both domestic and international markets [19][28]. Summary by Sections 1. TCM Industry Overview - TCM is defined as medicines guided by traditional Chinese medical theories, primarily sourced from natural products, including plant, animal, and mineral-based drugs. It is categorized into five main types: raw materials, decoction pieces, formula granules, proprietary Chinese medicines, and injectable TCM [12][13]. - The historical development of TCM has undergone three major phases, including skepticism during the introduction of Western medicine, a resurgence in the 21st century, and recent government initiatives to modernize and industrialize TCM [15][16]. 2. TCM Policy Analysis - The overall policy direction is supportive, with multiple government documents issued to encourage the high-quality development of the TCM industry. Key policies include the "Opinions on Promoting the Inheritance and Innovation of TCM" and various local measures [24][28]. - Policies cover supply-side improvements, such as optimizing TCM registration and approval processes, enhancing talent training, and building TCM hospitals [28][32]. - Payment reforms are also underway, exploring payment methods that align with TCM characteristics, which could enhance the financial viability of TCM services [45][46]. 3. Future Development Trends - Innovation in TCM is identified as a critical factor for future growth, with a focus on developing new formulations and improving the sustainability of TCM resources [61][63]. - TCM is positioned to become a significant player in the broader health and wellness market, emphasizing preventive care and holistic health approaches [66].

| 权益变动方向 | 比例增加☑ | | 比例减少□ | | --- | --- | --- | --- | | 权益变动前合计比例 | 28.91% | | | | 权益变动后合计比例 | 29.00% | | | | 本次变动是否违反已作出的承 诺、意向、计划 | 是□ | 否☑ | | | 是否触发强制要约收购义务 | 是□ | 否☑ | | 一、 信息披露义务人及其一致行动人的基本信息 证券代码：600587 证券简称：新华医疗 公告编号：临 2025-041 山东新华医疗器械股份有限公司 关于控股股东增持计划进展暨权益变动触及 1%刻度的提示性公告 控股股东山东颐养健康产业发展集团有限公司保证向本公司提供的信息真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 本次权益变动为山东新华医疗器械股份有限公司（以下简称"公司"） 控股股东山东颐养健康产业发展集团有限公司（以下简称"山东健康集团"）按 照增持计划增持公司股份，不触及要约收购，不会导致公司控股股东及实际控制 人发生变化。 本次权益变动后，山东健康集团合计 ...

Core Viewpoint - The company, Shandong Xinhua Medical Instrument Co., Ltd., is set to hold an investor briefing on October 16, 2025, to discuss its 2025 semi-annual performance and financial results, allowing for interactive communication with investors [2][3]. Group 1: Meeting Details - The investor briefing will take place on October 16, 2025, from 15:00 to 16:00 [2][8]. - The location for the meeting is the Shanghai Stock Exchange Roadshow Center, accessible online [2][8]. - The meeting will be conducted in an interactive online format, enabling real-time communication with investors [3][5]. Group 2: Participation Information - Investors can submit questions from October 9, 2025, to October 15, 2025, by visiting the Roadshow Center's website or via the company's email [6][9]. - The company will address commonly asked questions during the briefing [3][6]. Group 3: Contact Information - Investors can reach out to the company for inquiries regarding the briefing through phone, fax, or email [7][9]. - Contact details include a phone number (0533-3587766) and fax (0533-3587768), with email correspondence directed to shinva@163.com [8][9].